

Optimizing Germline Mutation Testing in Breast Cancer

Clinical Brief 1 – Updated Germline Testing Guidelines in Breast Cancer

Tweet 2 Reference:

Kudrik F, et al. Assessing BRCA1/2 testing in breast cancer patients: a retrospective analysis of real-world data From the IntegraConnect PrecisionQ de-identified database SABCS 2024. Abstract P1-01-15.

Additional References:

Arun B, Couch FJ, Abraham J, Tung N, Fasching PA. BRCA-mutated breast cancer : the unmet need, challenges and therapeutic benefits of genetic testing. *Br J Cancer*. 2024 Nov;131(9):1400-1414.

Bedrosian I, Somerfield MR, Achatz MI, et al. Germline testing in patients with breast cancer: ASCO-Society of Surgical Oncology guideline. *J Clin Oncol*. 2024 Feb 10;42(5):584-604.

Manahan ER, Kuerer HM, Sebastian M, et al. Consensus guidelines on genetic testing for hereditary breast cancer from the American Society of Breast Surgeons. *Ann Surg Oncol*. 2019;26(10):3025-3031.

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate (v2.2025). Updated November 07, 2024.

Pensabene M, Calabrese A, von Arx C, Caputo R, De Laurentiis M. Cancer genetic counselling for hereditary breast cancer in the era of precision oncology. *Cancer Treat Rev*. 2024 Apr;125:102702.

Stout LA, Hunter C, Schroeder C, Kassem N, Scheider BP. Clinically significant germline pathogenic variants are missed by tumor genomic sequencing. *NPJ Genom Med*. 2023 Oct 13;8:30.

Terraf P, Pareja F, Brown DN, et al. Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing. *Ann Oncol*. 2022 Apr;33(4):426-433.

Tung N, Ricker C, Messersmith, H, et al. Selection of germline genetic testing panels in patients with cancer: ASCO guideline. *J Clin Oncol*. 2024;42(5):584-604.

Glossary

ASBrS, American Society of Breast Surgeons

ASCO, American Society of Clinical Oncology

EBC, early breast cancer

ER, estrogen receptor

HER2, human epidermal growth factor receptor 2

IHC, immunohistochemistry

NCCN, National Comprehensive Cancer Network

PARP, poly (ADP-ribose) polymerase

PR, progesterone receptor

SSO, Society of Surgical Oncology

TNBC, triple-negative breast cancer

w/, with